EE370 Cost-Effectiveness Analysis of Pembrolizumab as Adjuvant Treatment for Resected Stage IIB/IIC Melanoma in Greece
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.636
https://www.valueinhealthjournal.com/article/S1098-3015(23)03766-X/fulltext
Title :
EE370 Cost-Effectiveness Analysis of Pembrolizumab as Adjuvant Treatment for Resected Stage IIB/IIC Melanoma in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03766-X&doi=10.1016/j.jval.2023.09.636
First page :
Section Title :
Open access? :
No
Section Order :
10124